

In the Claims:

1. (currently amended) A transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising:
- a backing layer; and
 - a reservoir supersaturated with active ingredients and containing oestradiol and norethisterone acetate, said reservoir is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, said polyacrylate consisting of carbon, hydrogen and oxygen; and [is] a detachable protective layer, wherein the crystallization inhibitor is an amino group-containing polymer selected from the group consisting of polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, polyamines, and polyglucosamines [and a copolymer based on butyl methacrylate, 2-dimethylaminoethyl methacrylate and methyl methacrylate being present in a molar ratio of 1:2:1 (butyl methacrylate : 2-dimethylaminoethyl methacrylate : methyl methacrylate)].
2. (Deleted)
3. (previously amended) A transdermal therapeutic system according to claim 1, wherein the reservoir comprises at least one crystallization inhibitor in proportion of from 0.05 to 30% by weight.
4. (previously amended) A transdermal therapeutic system according to claim 1, wherein the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:2 to 1:15, and in an overall concentration of up to 25% by weight.
5. (previously amended) A transdermal therapeutic system according to claim 1, wherein

the reservoir includes a constituent from the group consisting of aging inhibitors, plasticizers, antioxidants and absorption improvers, the plasticizers being used in a concentration of 0 to 5% by weight and the aging inhibitor in a concentration of 0.1 to 2% by weight.

- C¹
cont.
6. (previously amended) A transdermal therapeutic system according to claim 1, wherein the pressure-sensitive adhesive is selected from the group consisting of a solvent-based adhesive, a dispersion adhesive, a hot-melt adhesive and a UV-crosslinkable adhesive.
 7. (previously amended) A transdermal therapeutic system according to claim 1, wherein the reservoir consists of at least two layers.
 8. (previously amended) A transdermal therapeutic system according to claim 1, wherein the reservoir has a layer thickness of 0.02 mm to 0.500 mm.
 9. (previously amended) A transdermal therapeutic system according to claim 1, wherein the reservoir is provided with an additional pressure-sensitive adhesive layer.
 10. (Deleted)
 11. (previously amended) A transdermal therapeutic system according to claim 4, wherein the reservoir comprises oestradiol and norethisterone acetate in a weight ratio of from 1:3 to 1:7.
 12. (previously amended) A transdermal therapeutic system according to claim 8, wherein the reservoir has a layer thickness of 0.030 to 0.200 mm.
 13. (previously amended) A transdermal therapeutic system according to claim 9, wherein the reservoir is provided with a pressure-sensitive adhesive margin.
 14. (previously amended) A transdermal therapeutic system according to claim 1, wherein

the reservoir is provided with a pressure-sensitive adhesive margin.

15. (currently amended) A method for providing a transdermal therapeutic system for therapeutic applications in human medicine, said method comprising:

applying said transdermal therapeutic system to the skin of a patient by applying a polyacrylate pressure-sensitive adhesive to said transdermal therapeutic system, said polyacrylate consisting of carbon, hydrogen and oxygen; and

controlling the release of oestradiol in combination with norethisterone acetate to the human skin by providing a reservoir in said transdermal therapeutic system, said reservoir being supersaturated with active ingredients and being attached to a backing layer, wherein said reservoir comprises at least one amino group-containing polymer and at least one adhesive selected from the group consisting of a polyacrylate pressure-sensitive adhesive layer and a pressure-sensitive adhesive margin.

16. (New) The transdermal therapeutic system as set forth in claim 1, wherein said polyacrylate consisting of carbon, hydrogen and oxygen, consists of monomer units consisting of carbon, hydrogen and oxygen.

17. (New) The method for producing a transdermal therapeutic system for therapeutic applications as set forth in claim 15, wherein said polyacrylate consisting of carbon, hydrogen and oxygen, consists of monomer units consisting of carbon, hydrogen and oxygen.

18. (New) A transdermal therapeutic system in plaster form for controlled release of oestradiol in combination with norethisterone acetate, comprising:

a backing layer; and

a reservoir supersaturated with active ingredients and containing oestradiol and norethisterone acetate, said reservoir is attached to said backing layer and is prepared using polyacrylate pressure-sensitive adhesives and crystallization inhibitors, said polyacrylate of said polyacrylate pressure-sensitive adhesive being free of amino groups; and a detachable protective layer, wherein the crystallization inhibitor is an amino group-containing polymer selected from the group consisting of polyaminoamides, polyaminoimidazolines, polyetherurethaneamines, polyamines, and polyglucosamines.

C¹
concl.